Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | TPO | P07202 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869934 | 0.83 | HDAC1 (0.55) | HDAC1CYP19A1CACNA1GCACNA1IMPO | |
| SCHEMBL27650131 | 0.81 | HDAC1 (0.54) | HDAC1CYP19A1CACNA1GCACNA1IMPO | |
| SCHEMBL5869947 | 0.81 | HDAC1 (0.50) | HDAC1CYP19A1CACNA1GCACNA1IMPO | |
| SCHEMBL28862067 | 0.77 | HDAC1 (0.50) | HDAC1CYP19A1CACNA1GCACNA1IMPO | |
| SCHEMBL28862061 | 0.77 | HDAC1 (0.44) | HDAC1CYP19A1CACNA1GCACNA1IMPO | |
| SCHEMBL10247346 | 0.77 | GFER (0.60) | HDAC1CYP19A1CACNA1GCACNA1IALDH1A1 | |
| SCHEMBL18496417 | 0.76 | ALDH1A1 (0.62) | HDAC1CYP19A1ALDH1A1KDM4ENPC1 | |
| SCHEMBL29014035 | 0.76 | ALDH1A1 (0.56) | HDAC1CACNA1GCACNA1ICYP3A4ALDH1A1 | |
| SCHEMBL18338327 | 0.76 | HDAC1 (0.46) | HDAC1CYP19A1CACNA1GCACNA1IMPO | |
| SCHEMBL18338599 | 0.75 | HDAC1 (0.42) | HDAC1CYP19A1CACNA1GCACNA1IMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225910-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
| US-8034933-B2 | graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110230445-A1 | Substituted Heteroaryls | PFIZER INC | 2011-09-22 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-7384948-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | HDAC1 696/4885CYP19A1 4458/4885CACNA1G 1/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | HDAC1 1352/4885CYP19A1 4319/4885CACNA1G 2688/4885 |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CCR10, CXCR3 | HDAC1 1701/4885CYP19A1 2486/4885CACNA1G 1302/4885 |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | HDAC1 2157/4885CYP19A1 4404/4885CACNA1G 925/4885 |
| US-20120225910-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | HDAC1 480/4885CYP19A1 628/4885CACNA1G 3324/4885 |
| US-20110230445-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | HDAC1 467/4885CYP19A1 622/4885CACNA1G 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.